🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

250 results for “AstraZeneca AB” Clear

  1. AZD0022, AZD0022, Erbitux 5 mg/mL solution for infusion

    AstraZeneca AB

    Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. AZD0292, Placebo for AZD0292

    AstraZeneca AB

    Bronchiectasis with chronic pseudomonas aeruginosa colonization

    phase 2 small molecule active

    1 trial

  3. AZD0486, AZD0486

    AstraZeneca AB

    Relapsed or Refractory Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  4. AZD0486, AZD0486, TOCILIZUMAB

    AstraZeneca AB

    B-Cell Acute Lymphoblastic Leukaemia

    phase 2 small molecule active

    1 trial

  5. AZD0516, AZD9574, AZD9574, AZD9574, AZD9574

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  6. AZD0780, AZD0780, AZD0780 Placebo, AZD0780

    AstraZeneca AB

    Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, which is a major risk factor for Cardiovascular Disease (CVD), such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.

    phase 2 small molecule active

    1 trial

  7. AZD0901, Rilvegostomig, DS-8201a

    AstraZeneca AB

    Locally Advanced Resectable Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. AZD1163 Placebo, AZD1163

    AstraZeneca AB

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  9. AZD2962, AZD2962

    AstraZeneca AB

    Myelodysplastic syndromes, Dysplastic chronic myelomonocytic leukaemia

    phase 2 small molecule active

    1 trial

  10. AZD3632, AZD3632

    AstraZeneca AB

    Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes

    phase 2 small molecule active

    1 trial

  11. AZD4360

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. AZD4512

    AstraZeneca AB

    Non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  13. AZD4512

    AstraZeneca AB

    B-cell acute lymphoblastic leukemia (B-ALL)

    phase 2 small molecule active

    1 trial

  14. AZD4604, AZD4604 Placebo, AZD4604

    AstraZeneca AB

    Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

    phase 2 small molecule active

    1 trial

  15. AZD4604, Azd4604 placebo, AZD4604

    AstraZeneca AB

    Asthma

    phase 2 small molecule active

    1 trial

  16. AZD5004, AZD5004, AZD5004, Rybelsus 14 mg tablets, Placebo to match AZD5004 (PTM) film-coated tablets, Rybelsus 7 mg tablets, Rybelsus 3 mg tablets

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  17. AZD5004, Placebo to match AZD5004 film coated tablet, AZD5004, AZD5004

    AstraZeneca AB

    Participants living with Obesity or Overweight with at least 1 comorbidity

    phase 2 small molecule active

    1 trial

  18. AZD5462, AZD5462, The AZD5462 film-coated tablet placebo contains microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, titanium dioxide, macrogol (polyethylene glycol) and talc. It is supplied in the same pack as the active and should be stored according to instructions on the label., AZD5462

    AstraZeneca AB

    Chronic Heart Failure

    phase 2 small molecule active

    1 trial

  19. AZD6738, Ceralasertib

    AstraZeneca AB

    Advanced Cancer Whose Tumours Contain Molecular Alterations

    phase 2 small molecule active

    1 trial

  20. AZD6738, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets, Ceralasertib, AZD6738

    AstraZeneca AB

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  21. AZD6793, AZD6793 Placebo, AZD6793, AZD6793

    AstraZeneca AB

    Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  22. AZD7789

    AstraZeneca AB

    Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma, Advanced or Metastatic Non-small Cell Lung Carcinoma, Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  23. AZD7798 Placebo, AZD7798

    AstraZeneca AB

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  24. AZD7798 Placebo: 0.9% saline solution for injection, commercially available., AZD7798

    AstraZeneca AB

    Crohn’s Disease and an Ileostomy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources